ArticleNeurochemical research2025
Costunolide Ameliorates the Methylmalonic Acidemia Via the PINK1/Parkin Pathway.
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Disturbances of Mitochondrial Functions and Oxidative Stress Induction in Methylmalonic and Propionic Acidemias: A Critical Role for Metabolite Accumulation.International journal of molecular sciences · 2026Review
- Metabolic toxicity and neurological dysfunction in methylmalonic acidemia: from mechanisms to therapeutics.Molecular medicine (Cambridge, Mass.) · 2025Review
- Crosstalk between mitochondrial dysfunction and benign prostatic hyperplasia: unraveling the intrinsic mechanisms.The Canadian journal of urology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Methylmalonic acidemia (MMA) is a congenital organic acidemia characterized by mitochondrial dysfunction due to the abnormal accumulation of intermediate metabolites, which subsequently leads to brain damage. Currently, there are no specific pharmacological treatments available for MMA in clinical practice. Costunolide (COS) is a sesquiterpenoid compound derived from Radix Aucklandiae, it exhibits a broad spectrum of bioactivities. However, its effects on MMA have not yet been evaluated. For in-vivo studies, the MMA rat model was established by subcutaneous injection of methylmalonic acid (MA). The spatial learning memory flexibility observed by Morris water maze and brain damage were restored in MMA rats after COS treatment. JC-1 detection and measurements of oxidative stress indicators were performed to demonstrate that the abnormal mitochondrial membrane potential (MMP) and oxidative stress levels were recovered in hippocampus of MMA rats after COS (20 mg/kg) treatment. The abnormal expression of autophagy-related proteins induced by MMA was also rectified following COS treatment. In-vitro research utilized PC12 cells to further investigate the underlying mechanisms of COS in regulating MMA. Our results indicated that COS (20µM) ameliorated the oxidative stress level and mitophagy. Pink1 knockdown reversed the apoptosis rate and MMP which were improved by COS (20µM). Concurrently, the beneficial effects of COS on ATP concentration, ROS level and autophagy related protein expression level were also offset by PINK1 knockdown. In conclusion, our study confirms that COS promotes mitochondrial autophagy and mitigates oxidative stress via the PINK1/Parkin pathway, thereby improving cognitive impairments associated with MMA.
Indexed as
Identifiers
40053170What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.